CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $300,936 | -19.1% | 6,630 | 0.0% | 0.06% | -4.4% |
| Q2 2023 | $372,209 | +24.1% | 6,630 | 0.0% | 0.07% | 0.0% |
| Q1 2023 | $299,875 | +11.3% | 6,630 | 0.0% | 0.07% | -27.7% |
| Q4 2022 | $269,510 | -37.8% | 6,630 | 0.0% | 0.09% | +3.3% |
| Q3 2022 | $433,000 | +7.4% | 6,630 | 0.0% | 0.09% | -5.2% |
| Q2 2022 | $403,000 | -3.1% | 6,630 | 0.0% | 0.10% | +39.1% |
| Q1 2022 | $416,000 | -92.3% | 6,630 | -80.1% | 0.07% | -90.5% |
| Q2 2021 | $5,403,000 | +63.2% | 33,376 | +22.9% | 0.73% | +53.7% |
| Q1 2021 | $3,310,000 | – | 27,163 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |